Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy?
Where this comes from
- Record sourced from PubMed, PMID 18004308.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Diabetic nephropathy is the leading cause of end-stage renal disease. Novel preventive measures for diabetic renal complications are urgently needed. Miyazaki et al. report that rosiglitazone, a thiazolidinedione insulin sensitizer and a potent peroxisome proliferator-activated receptor gamma agonist, not only effectively improves glycemic control but also halts progression of albuminuria in type 2 diabetic patients with early-stage diabetic nephropathy. These findings could offer a new prevention of diabetic nephropathy in insulin-resistant diabetic patients.
Medical subject headings
- Diabetic Nephropathies
- Thiazolidinediones